

## State of Oklahoma SoonerCare Blenrep (Belantamab Mafodotin-blmf) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	<b>Drug Information</b>	
□Physician billing (HCPCS code:) □Pharmacy billing (NDC:		villing (NDC:)
Dose: Re	Regimen: Start Date (or date of next dose):	
	Billing Provider Inform	ation
Provider NPI:	Provider Name:	
	Prescriber Informati	on
Prescriber NPI:		
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
YesNo B. Has the membe i. If yes, please	ceive eye exams, including visual acunt cycle (every 3 weeks)? Yesf the above, please indicate diagno	Yes No pies member has received: oteasome inhibitor her: ity and slit lamp ophthalmic examinations,
Yes No	evidence of progressive disease while enced adverse drug reactions related	le on belantamab mafodotin-blmf? to belantamab mafodotin-blmf therapy?
the best of my knowledge.	treatment is medically necessary a	Date:and all information is true and correct to necessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.